Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INZYNASDAQ:LIMNNASDAQ:PDSBNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINZYInozyme Pharma$4.00$3.21$0.72▼$6.24$258.25M2.27927,189 shsN/ALIMNLiminatus Pharma$8.42-6.7%$0.00$4.40▼$33.66$219.00MN/A351,476 shs60,482 shsPDSBPDS Biotechnology$1.24-7.1%$1.46$0.85▼$4.42$56.82M1.21471,961 shs68,505 shsTNXPTonix Pharmaceuticals$34.74-2.1%$30.54$6.76▼$130.00$255.69M2.05957,589 shs201,137 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINZYInozyme Pharma0.00%+0.25%+0.25%+342.53%-10.91%LIMNLiminatus Pharma0.00%-4.85%+901,999,900.00%+901,999,900.00%+901,999,900.00%PDSBPDS Biotechnology0.00%-5.25%-20.95%+38.70%-57.18%TNXPTonix Pharmaceuticals0.00%+1.75%-12.67%+99.44%-55.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINZYInozyme Pharma3.4078 of 5 stars4.24.00.00.01.92.50.0LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/APDSBPDS Biotechnology2.3384 of 5 stars3.74.00.00.02.30.00.0TNXPTonix Pharmaceuticals2.5837 of 5 stars3.52.00.00.01.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINZYInozyme Pharma 2.44Hold$11.75193.75% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/APDSBPDS Biotechnology 3.33Buy$9.00628.74% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,583.89% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, INZY, TNXP, and LIMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.004/10/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/8/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ATNXPTonix Pharmaceuticals$10.09M25.34N/AN/A$31.82 per share1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/APDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest PDSB, INZY, TNXP, and LIMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINZYInozyme PharmaN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINZYInozyme Pharma0.652.192.19LIMNLiminatus PharmaN/AN/AN/APDSBPDS Biotechnology0.292.332.33TNXPTonix PharmaceuticalsN/A12.3111.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINZYInozyme Pharma88.30%LIMNLiminatus PharmaN/APDSBPDS Biotechnology26.84%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipINZYInozyme Pharma12.18%LIMNLiminatus PharmaN/APDSBPDS Biotechnology9.20%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableLIMNLiminatus PharmaN/A26.01 millionN/AN/APDSBPDS Biotechnology2045.71 million41.51 millionOptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionablePDSB, INZY, TNXP, and LIMN HeadlinesRecent News About These CompaniesTonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox4 hours ago | quiverquant.comQTonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 20255 hours ago | globenewswire.comTNXP Tonix Pharmaceuticals Holding Corp. - Seeking AlphaJuly 4 at 11:21 PM | seekingalpha.comTonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer ModelsJuly 2, 2025 | quiverquant.comQTonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal ModelsJuly 2, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% - Here's WhyJuly 1, 2025 | marketbeat.comTonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexesJune 30, 2025 | msn.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 2.4% - Should You Buy?June 30, 2025 | marketbeat.comTonix Pharmaceuticals to be added to Russell 3000, Russell 2000 indexesJune 30, 2025 | seekingalpha.comTonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 30, 2025 | globenewswire.comTonix Pharmaceuticals Holding Corp. - TNXP | Barron'sJune 29, 2025 | barrons.comTNXP | Tonix Pharmaceuticals Holding Corp. Stock Overview (U.S.: Nasdaq) - Barron'sJune 27, 2025 | barrons.comTonix Pharmaceuticals Holding Corp News (TNXP) - Investing.comJune 27, 2025 | investing.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 2.4% - Here's WhyJune 27, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.7% - Still a Buy?June 26, 2025 | marketbeat.comTonix Pharmaceuticals Holding Corp TNXP Company Vitals - U.S. NewsJune 26, 2025 | money.usnews.comTNXP - Tonix Pharmaceuticals Holding Corp News - MorningstarJune 26, 2025 | morningstar.comMTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.3% - Time to Sell?June 25, 2025 | marketbeat.comRhumbline Advisers Invests $244,000 in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)June 25, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 5% - What's Next?June 24, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Should You Sell?June 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDSB, INZY, TNXP, and LIMN Company DescriptionsInozyme Pharma NASDAQ:INZY$4.00 0.00 (0.00%) As of 07/1/2025Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Liminatus Pharma NASDAQ:LIMN$8.42 -0.60 (-6.65%) As of 10:37 AM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.PDS Biotechnology NASDAQ:PDSB$1.24 -0.10 (-7.14%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Tonix Pharmaceuticals NASDAQ:TNXP$34.74 -0.74 (-2.08%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story CAVA Group: Why the Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
